As GLP-1 receptor agonists reshape obesity treatment, a new medical perspective published in JAMA, underscores a persistent ...

The National Psoriasis Foundation has issued a statement that endorses consideration of adjunctive GLP-1 receptor agonists in ...

USA: Emerging evidence indicates that GLP-1 receptor agonists may play a supportive role alongside standard psoriasis ...

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and ...

This innovative compound is known as a 'quintuple agonist' because it combines the power of GLP-1 and glucose-dependent ...

GLP-1 receptor agonists may not raise the risk for diabetic ketoacidosis or pancreatitis among adults with type 1 diabetes, ...

A new GLP-1 weight loss drug called survodutide has shown promising results in a phase 3 clinical trial. The drug, which ...

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, ...

Several studies have served up tantalizing hints about the drugs’ potential cancer prevention benefits, but other results ...

Doctronic reports new AI analysis reveals GLP-1 medications may cause underreported symptoms like menstrual irregularities ...

Researchers found that GLP-1 receptor agonist initiation was associated with a reduced risk for disorders related to alcohol, cannabis, cocaine, nicotine, and opioid use. HealthDay News — The use of ...

The researchers found that GLP-1 RA use was associated with significantly lower odds of vertebral compression fractures compared with nonuse. (HealthDay News) — Glucagon-like peptide 1 receptor ...